Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B J Monk

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Gynecologic Oncology|February 18, 1999
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancerR A Burger, P J DiSaia, J A Roberts, et al.
British Journal of Cancer|September 11, 2003
HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3J K Chan, B J Monk, C Brewer, et al.
Gynecologic Oncology|July 27, 2017
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) studyN T Phippen, A A Secord, S Wolf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2024
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancerG Bogani, B J Monk, M A Powell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2015
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 studyB J Monk, P Ghatage, T Parekh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialA Poveda, I Vergote, S Tjulandin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free intervalS B Kaye, N Colombo, B J Monk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)K Fujiwara, B J Monk, C Lhommé, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2024
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 studyD Lorusso, N Colombo, C Dubot, et al.
Archives of Gynecology and Obstetrics|April 23, 2019
A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancerG F Vercellino, E Erdemoglu, P Lichtenberg, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Gynecologic Oncology|February 18, 1999
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancerR A Burger, P J DiSaia, J A Roberts, et al.
British Journal of Cancer|September 11, 2003
HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3J K Chan, B J Monk, C Brewer, et al.
Gynecologic Oncology|July 27, 2017
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) studyN T Phippen, A A Secord, S Wolf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2024
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancerG Bogani, B J Monk, M A Powell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2015
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 studyB J Monk, P Ghatage, T Parekh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialA Poveda, I Vergote, S Tjulandin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free intervalS B Kaye, N Colombo, B J Monk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)K Fujiwara, B J Monk, C Lhommé, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2024
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 studyD Lorusso, N Colombo, C Dubot, et al.
Archives of Gynecology and Obstetrics|April 23, 2019
A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancerG F Vercellino, E Erdemoglu, P Lichtenberg, et al.
Pageof 7